Proteomics International Advances Commercial Launch of Three Blood-Based Diagnostic Tests with Exclusive Healius Partnership

Clinically Validated Blood Tests Addressing Major Chronic Diseases

Proteomics International’s diagnostic portfolio includes four tests, with three prioritized for commercial focus. Promarker4D is a prognostic blood test predicting risk of diabetes-related chronic kidney disease up to four years before clinical symptoms, enabling earlier intervention and monitoring. It demonstrates 7695% sensitivity, 9295% specificity, 9597% negative predictive value, and an area under the curve (AUC) of 0.7890.88, supporting risk stratification in diabetes care and renal risk pathways.

Promarker4Eso targets patients with chronic reflux symptoms, detecting protein changes to rule out oesophageal adenocarcinoma and reduce the need for invasive surveillance endoscopy. It shows 91% sensitivity, 98% specificity, 99.9% negative predictive value, and an AUC above 0.98, making it ideal for triaging reflux patients within gastroenterology referral pathways. Promarker4Endo supports assessment of women with symptoms suggestive of endometriosis, delivering 83% sensitivity, 95% specificity, 75% negative predictive value, and an AUC exceeding 0.92, helping address diagnostic delays in this underdiagnosed condition.

Exclusive Partnership with Healius Secures Australian Market Access

Proteomics International has secured an exclusive three-year agreement with Healius, providing access to more than 2,000 collection centres and established referrer networks across Australia. This exclusive arrangement, with a mutual extension option, eliminates direct competition within Healius’s collection infrastructure, positioning Proteomics International as the sole supplier of its diagnostic tests through this major pathology provider.

The partnership accelerates market entry compared to building independent distribution channels, leveraging Healius’s established referrer relationships to facilitate test adoption and integration into routine clinical workflows. It also offers revenue growth potential as adoption increases among clinicians and pathologists within the network, reflecting Healius’s confidence in the clinical validity and market opportunity of Proteomics International’s diagnostics.

Proteomics-Based Diagnostics Offer Superior Insights Beyond Genomics

Proteomics International specialises in protein analysis diagnostics, focusing on proteins that directly drive disease activity. This approach provides richer clinical insights than genomics alone, as proteins are active molecules involved in disease progression. By identifying and validating protein biomarkers specific to disease states, the company’s tests capture disease activity and risk with greater functional relevance than DNA-based tests.

The company’s competitive edge derives from in-house expertise spanning biomarker discovery, clinical validation, and compliant laboratory operations. This vertical integration enables faster development cycles, stringent quality control, and regulatory compliance. The focus on minimally invasive blood tests aligns with clinical preferences and supports accessibility across diverse healthcare settings.

Laboratory Infrastructure Certified for Australian and US Markets

Proteomics International operates accredited laboratories in Australia and the United States, covering two major diagnostic markets. The Australian lab holds NATA accreditation, while the US facility maintains CLIA certification and CAP accreditation, which exceeds CLIA standards. This dual certification supports commercial launches and reimbursement efforts in both countries, each with unique regulatory and payment systems.

Investment in these validated laboratories reflects the capital-intensive nature of regulated diagnostics and creates barriers to entry for competitors. Ongoing compliance audits, quality assurance, and staff competency requirements embed operational rigor, enabling the generation of real-world evidence during controlled market release phases to support reimbursement applications.

Phased Commercial Strategy Emphasizes Validation, Readiness, and Reimbursement

The company’s structured commercial roadmap prioritizes completing validation, ensuring laboratory readiness, managing controlled market release, advancing reimbursement pathways, and expanding into the US market. This approach acknowledges the need for clinical utility evidence beyond validation before broad adoption and reimbursement. Ongoing validation includes independent cohort studies, particularly for Promarker4Endo, to strengthen reproducibility and clinical relevance.

Laboratory readiness involves process automation, quality protocols, turnaround time optimization, and staff training for scaled testing. Controlled market release allows demand management, real-world data collection, clinician education, and operational refinement before full commercialization. This phased rollout mitigates reimbursement risks by building evidence of clinical utility and cost-effectiveness through private-pay markets prior to formal reimbursement applications, reflecting mature commercial discipline focused on sustainable growth.

Hybrid Reimbursement Model Combines Private-Pay and Evidence Generation

Proteomics International employs a hybrid reimbursement strategy, generating private-pay revenue during early commercialization while systematically gathering evidence to support sustainable reimbursement coverage. This acknowledges that Australian and US payers—including Medicare, private insurers, and integrated health systems—require robust clinical and economic data before approving coverage.

Private-pay revenue funds evidence generation without premature reimbursement submissions lacking outcome data. The evidence collected demonstrates real-world test performance, clinical workflow integration, health outcome improvements, and cost savings compared to existing diagnostics. For example, Promarker4Eso could reduce unnecessary endoscopies and related costs; Promarker4D could quantify benefits of earlier intervention in chronic kidney disease; Promarker4Endo could document faster diagnosis and improved management. This data-driven approach enhances reimbursement approval prospects and potential coverage levels.

Significant Market Opportunities in Australia and the United States

Market assessments for the three lead tests in Australia and the US consider population size and disease prevalence. Promarker4D targets Type 2 diabetes patients at risk of chronic kidney disease, a large population segment. Promarker4Eso addresses patients with chronic reflux symptoms needing oesophageal adenocarcinoma surveillance, currently reliant on invasive endoscopy. Promarker4Endo serves women with symptoms of endometriosis, a common condition among reproductive-age women.

These addressable markets offer substantial growth potential based on achievable penetration. The dual-market strategy diversifies reimbursement and market access risks across two distinct healthcare systems. Success in either geography supports revenue scale and clinical validation, facilitating expansion. The company aims for recurring test revenues driven by adoption among clinicians and patients, creating predictable volume-based income once reimbursement is secured.

Focused Capital Allocation and Strategic Commercial Priorities Drive Repositioning

Proteomics International has realigned its business strategy around focused commercial priorities, enhanced accountability, and disciplined capital allocation. This shift moves away from broad R&D across multiple candidates toward commercializing three lead tests with strong clinical evidence and clear market pathways. The disciplined capital approach emphasizes governance over spending, prioritizing initiatives with clear commercial returns and milestone accountability.

This strategy addresses the capital-intensive nature of diagnostic development and commercialization by managing cash burn through focused investment rather than parallel development. For investors, this indicates management’s commitment to extending cash runway, achieving positive cash flow before capital depletion, and potentially reducing future capital raises. This approach is crucial for a clinical-stage diagnostics firm where market access, reimbursement, and private-pay revenue typically take 12 to 36 months to materialize.

Diagnostic Portfolio Meets Unmet Clinical Needs in High-Impact Diseases

Each test targets a significant clinical gap. Promarker4D addresses variability in progression to chronic kidney disease among Type 2 diabetes patients, offering earlier risk detection than current tools and enabling preventive care to reduce end-stage renal disease and costs. Promarker4Eso aims to lower the burden of repeated invasive endoscopies for oesophageal adenocarcinoma surveillance in reflux patients by providing a blood-based rule-out test, reducing procedural risks and patient anxiety. Promarker4Endo tackles the prolonged diagnostic delay in endometriosis, which averages 7 to 10 years, by supporting earlier specialist referral and diagnosis, thereby improving patient outcomes and access to treatment.

Reimbursement Delays and Private-Pay Limitations Present Execution Risks

Despite clinical validation and market infrastructure, reimbursement delays or denials remain significant risks if payers find health economic evidence insufficient. In Australia, the Medicare Benefits Schedule, and in the US, Medicare, Medicaid, and private insurers require comprehensive dossiers including economic modeling and outcome data to approve coverage. Established diagnostic approaches, despite limitations, may delay acceptance of newer tests even with superior performance.

Private-pay revenue is constrained by patients’ willingness and ability to pay out-of-pocket, especially where public coverage exists. In Australia, Medicare pathology coverage often leads patients to default to publicly funded diagnostics. In the US, private-pay testing competes with direct-to-consumer companies and discounted pathology networks. Private-pay income alone may not sustain operations or evidence generation without timely reimbursement, making execution of the reimbursement strategy critical to managing cash burn and achieving profitability.